K. Swenerton

Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.

K. Swenerton, J Jeffrey, Gavin Stuart et al. · Journal of Clinical Oncology · 1992 · 214 citations

Medicine, Gynecology, Oncology +17

Amplification of 11q13 in ovarian carcinoma

Lindsay Brown, Steve E. Kalloger, Melinda A. Miller et al. · Genes Chromosomes and Cancer · 2008 · 183 citations

Medicine, Genetics, Oncology +13

Oral etoposide is active against platinum-resistant epithelial ovarian cancer.

Paul Hoskins, K. Swenerton · Journal of Clinical Oncology · 1994 · 171 citations

Medicine, Oncology, Pharmacology +16

Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer

Martine Piccart, K. Bertelsen, Gavin Stuart et al. · International Journal of Gynecological Cancer · 2003 · 122 citations

Medicine, Gynecology, Oncology +13

Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.

Karen A. Gelmon, Hal W. Hirte, A. Robidoux et al. · Journal of Clinical Oncology · 2010 · 103 citations

Medicine, Oncology, Pharmacology +17